Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Appl Lab Med ; 4(3): 433-438, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31659082

RESUMEN

BACKGROUND: Lactate dehydrogenase (LDH) is a nonspecific biomarker for diseases including lymphoma. Serum and plasma are generally considered interchangeable for LDH testing. Investigation into falsely increased plasma LDH concentration results led to the hypothesis that a workflow change that included pneumatic tube system (PTS) transportation caused the errors. The following study was conducted to test the hypothesis. METHODS: Plasma and serum separator tube samples were each drawn in duplicate, centrifuged, transported either through the PTS or by hand courier, and evaluated by means of clinical chemistry and hematology assays. Smear slides were made out of the plasma and examined. Aggregate patient results before and after the PTS workflow change were compared. RESULTS: In post-PTS plasma samples, LDH activity was 26%-149% higher. Similarly, white blood cells (WBCs) were 14- to 156-fold higher and platelets were 1- to 13-fold higher. Smear examination revealed dramatically more cells and cell fragments. No significant hemolysis was observed in plasma by chemistry hemolysis indices or hemoglobin testing. These effects were not observed in similarly transported serum samples in gel separator tubes. Aggregate LDH patient results, including moving medians, demonstrated dramatic changes following PTS workflow implementation. CONCLUSIONS: PTS transportation led to falsely increased LDH concentration in plasma. These LDH concentration elevations are not heralded by standard indicators of hemolysis. These errors can be prevented by restricting LDH concentration testing to serum collected in gel separator tubes. Moving patient statistics can effectively detect important testing process changes not revealed by external QC or indices.


Asunto(s)
Análisis Químico de la Sangre/métodos , Fenómenos Fisiológicos Sanguíneos , Recolección de Muestras de Sangre , L-Lactato Deshidrogenasa/sangre , Manejo de Especímenes , Análisis Químico de la Sangre/normas , Recolección de Muestras de Sangre/métodos , Recolección de Muestras de Sangre/normas , Hemólisis , Humanos , Manejo de Especímenes/métodos , Manejo de Especímenes/normas , Transportes
2.
Adv Anat Pathol ; 26(4): 241-245, 2019 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-30950848

RESUMEN

Testicular germ cell tumors are a diverse group of neoplasms, consisting of the prepubertal type 1 tumors, pure teratoma, and pure yolk sac tumor, the type 2 tumors, which are biologically malignant, preceded by germ cell neoplasia in situ, and harbor chromosome 12p abnormalities, and the type 3 tumor, spermatocytic tumor, which features chromosome 9p amplification. These arise in distinct clinical settings, and harbor distinct genetic abnormalities, immunohistochemical properties, and morphologic features. Here we have attempted to unify embryology, morphology, immunohistochemistry, and genetics in order to distill this fascinating group of neoplasms into what we hope is a useful framework for understanding their classification.


Asunto(s)
Biomarcadores de Tumor/genética , Tumor del Seno Endodérmico/patología , Neoplasias de Células Germinales y Embrionarias/patología , Neoplasias Testiculares/patología , Aberraciones Cromosómicas , Células Germinativas/patología , Humanos , Neoplasias de Células Germinales y Embrionarias/diagnóstico , Neoplasias de Células Germinales y Embrionarias/genética , Neoplasias Testiculares/diagnóstico , Neoplasias Testiculares/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA